ProCE Banner Activity

SELECT-MONOTHERAPY Long-Term Extension: Phase III Trial of Upadacitinib in Patients With Rheumatoid Arthritis

Slideset Download
Monotherapy with the investigational JAK1 inhibitor upadacitinib showed sustained clinical improvements and safety outcomes through 48 weeks in patients with RA with inadequate response to methotrexate.

Released: June 24, 2019

Expiration: June 22, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals